Comprehensive genomics, systems, and structural assessment for novel target identification in penicillin-resistant Streptococcus pneumoniae
Frontiers in Bioinformatics · 29.04.2026 · 6
DOI: 10.3389/fbinf.2026.1784287 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Bioinformatics, online erschienen am 29.04.2026. Verfasst von Avani Panickar und 4 weiteren Autor:innen. Beteiligte Einrichtung: Medical and Biological Computing Laboratory, School of Biosciences and Technology, Vellore Institute of Technology (VIT), Vellore, Tamil Nadu, India. Die Arbeit nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: VIT University.
Abstract (Originalsprache)
Introduction
The increasing prevalence of penicillin-resistant Streptococcus pneumoniae (PRSP) has compromised the efficacy of conventional β-lactam therapies, and the inefficiency of penicillin-binding proteins (PBPs) as reliable drug targets further underscores the urgent need to explore novel alternatives. The current study employs an in silico strategy that integrates genomics, genome-wide association studies (GWASs), network analyses, and membrane protein simulations to systematically identify and prioritize new antimicrobial targets. Methodology A total of 665 PRSP genomes from Indian clinical isolates collected between 1996 and 2022 were analyzed. High-quality genome assemblies were annotated and used for pangenome construction and GWASs to identify gene clusters associated with penicillin resistance. Candidate genes were further prioritized through essentiality screening, functional annotation, subcellular localization prediction, evolutionary conservation analysis, druggability assessment, and structural modeling.
Results
Integrated analysis identified OppC2, an essential oligopeptide permease of the ABC transporter family, as a highly favorable drug target. Network and functional enrichment analyses linked OppC2 to transport-associated pathways relevant to pneumococcal survival and adaptation. Structural modeling revealed a high-confidence protein model with a druggable binding pocket, while molecular dynamics simulations confirmed the stability of the structure in a physiological membrane environment.
Conclusion
This comprehensive approach enabled the identification of conserved, essential, and accessible drug targets within PRSP populations, providing an adaptable framework to guide next-generation antimicrobial target identification beyond traditional PBPs.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Medical and Biological Computing Laboratory, School of Biosciences and Technology, Vellore Institute of Technology (VIT), Vellore, Tamil Nadu, India.
- Department of Biosciences, School of Biosciences and Technology, Vellore Institute of Technology (VIT), Vellore, Tamil Nadu, India.
- Department of Biotechnology, School of Biosciences and Technology, Vellore Institute of Technology (VIT), Vellore, Tamil Nadu, India.
- Infectious Diseases Medical and Scientific Affairs, GlaxoSmithKline (GSK), Worli, Maharashtra, India.
Förderung
- VIT University
Zitieren
APA
Panickar, A., Anbarasu, S., Manoharan, A., Ramaiah, S., & Anbarasu, A. (2026). Comprehensive genomics, systems, and structural assessment for novel target identification in penicillin-resistant Streptococcus pneumoniae. Frontiers in Bioinformatics, 6. https://doi.org/10.3389/fbinf.2026.1784287
Vancouver
Panickar A, Anbarasu S, Manoharan A, Ramaiah S, Anbarasu A. Comprehensive genomics, systems, and structural assessment for novel target identification in penicillin-resistant Streptococcus pneumoniae. Frontiers in Bioinformatics. 2026;6. doi:10.3389/fbinf.2026.1784287
BibTeX
@article{Panickar2026,
author = {Panickar, Avani and Anbarasu, Suvitha and Manoharan, Anand and Ramaiah, Sudha and Anbarasu, Anand},
title = {Comprehensive genomics, systems, and structural assessment for novel target identification in penicillin-resistant Streptococcus pneumoniae},
journal = {Frontiers in Bioinformatics},
year = {2026},
volume = {6},
doi = {10.3389/fbinf.2026.1784287}
}
EUVIMED